Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Dominique N LisieroMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI 53705.
Zhang ChengDepartment of Microbiology, Immunology, and Molecular Genetics, Institute for Quantitative and Computational Biosciences and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90025.ORCID 0000-0003-3863-2866
Melba M TejeraDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706.
Brandon T NeldnerDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706.ORCID 0000-0003-4278-4045
Jay W WarrickMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI 53705.ORCID 0000-0002-4801-8897
Shelly M Wuerzberger-DavisMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI 53705.
Alexander HoffmannDepartment of Microbiology, Immunology, and Molecular Genetics, Institute for Quantitative and Computational Biosciences and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90025.ORCID 0000-0002-5607-3845
M SureshDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706; sureshm@vetmed.wisc.edu smiyamot@wisc.edu.ORCID 0000-0003-1794-3358
Shigeki MiyamotoMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI 53705; sureshm@vetmed.wisc.edu smiyamot@wisc.edu.ORCID 0000-0002-7827-3426
University of Wisconsin–Madison · USQB3 · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Novel Combination Adjuvant for Eliciting Systemic and Mucosal CD8 T Cell MemoryU01AI124299 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, BRUCE STEVEN, SURESH, MARULASIDDAPPA · 2016 to 2025
$6.2M
MECHANISMS OF CONSTITUTIVE NF KB ACTIVITYR01CA081065 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MIYAMOTO, SHIGEKI · 1999 to 2007
$2.5M
Cell decision underlying B-cell immune responsesR01AI132731 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOFFMANN, ALEXANDER · 2018 to 2022
$2.2M
Molecular and Cellular Mechanisms of Tumor DevelopmentT32CA157322 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALEXANDER, CAROLINE M · 2011 to 2017
$1.6M
Multi-color Benchtop Flow CytometerS10RR025483 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI BUSHMAN, WADE A · 2009 to 2009
$449k
Mucosal Adjuvant to Induce Multipronged T Cell Immunity to TuberculosisR21AI149793 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SURESH, MARULASIDDAPPA · 2020 to 2021
$427k
Regenerative Capacity of Anti-Viral Memory CD8 T cellsR21AI118326 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SURESH, MARULASIDDAPPA · 2016 to 2017
$409k
Special BD LSR FortessaS10OD018202 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI PATANKAR, MANISH S · 2014 to 2014
$351k
Mechanisms of constitutive NF-kB activityR56CA081065 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MIYAMOTO, SHIGEKI · 2009 to 2009
$251k
Regulation of T cell differentiation by nuclear export of NF-kB inhibitor, IkBaF32AI112206 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI LISIERO, DOMINIQUE N · 2015 to 2015
Optimal CD8 T cell immunity is orchestrated by signaling events initiated by TCR recognition of peptide Ag in concert with signals from molecules such as CD28 and 4-1BB. The molecular mechanisms underlying the temporal and spatial signaling dynamics in CD8 T cells remain incompletely understood. In this study, we show that stimulation of naive CD8 T cells with agonistic CD3 and CD28 Abs, mimicking TCR and costimulatory signals, coordinately induces 4-1BB and cRel to enable elevated cytosolic cRel:IκBα complex formation and subsequent 4-1BB-induced IκBα degradation, sustained cRel activation, heightened IL-2 production and T cell expansion.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
IκBα Nuclear Export Enables 4-1BB-Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity. · full record | OpenQuestion